Literature DB >> 1371242

DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.

L B Owen-Schaub1, S Yonehara, W L Crump, E A Grimm.   

Abstract

Fas is a mouse monoclonal antibody-defined cell surface antigen of an unknown physiologic function. Previous studies demonstrated that the anti-Fas antibody mediated apoptosis in those cells sensitive to tumor necrosis factor (TNF) and, further, triggered the co-downregulation of tumor necrosis factor receptors (TNF-Rs). These findings led to speculation that Fas may be associated with TNF-Rs. The present studies were undertaken as an extension of our previous work on the obligate requirement for TNF in development and maintenance of cytotoxic lymphocytes and were designed to analyze the expression and consequences of Fas engagement in these cells. Herein, we demonstrate that, in contrast to TNF-R expression, both resting and IL-2-activated lymphocytes express Fas. In accordance with previous studies using tumor cell lines, lymphocytes rapidly downregulate TNF-Rs after treatment with anti-Fas. The ability of anti-Fas to mediate apoptotic cell death in lymphocytes, however, was dependent upon the status of cellular activation. For example, lymphocytes activated in IL-2 for longer than 4 days underwent rapid DNA fragmentation and cell death after anti-Fas treatment. Despite their expression of Fas, nonactivated lymphocytes and those activated for periods less than 4 days were refractory to antibody-mediated cell killing. Because anti-Fas-mediated lethality is selective for chronically activated lymphocytes, Fas may prove to be an appropriate target for immunosuppressive intervention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371242     DOI: 10.1016/0008-8749(92)90187-t

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  66 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

2.  Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

Authors:  M Di Renzo; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

3.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L).

Authors:  D C Huang; M Hahne; M Schroeter; K Frei; A Fontana; A Villunger; K Newton; J Tschopp; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Enhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RS.

Authors:  M Di Renzo; D Serrano; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

5.  Programmed cell death (apoptosis) in cord blood lymphocytes.

Authors:  S Aggarwal; A Gupta; S Nagata; S Gupta
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

Review 6.  Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95).

Authors:  B Z Stanger
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

Review 7.  Regulation of apoptosis in immune cells.

Authors:  J D Mountz; T Zhou; J Wu; W Wang; X Su; J Cheng
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

8.  Influence of the lpr environment on the lymph node cell phenotypes in C57BL/6 nubg and nulpr chimeras.

Authors:  F Tiberghien; R Ceredig; F Loor
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.

Authors:  D Ashany; X Song; E Lacy; J Nikolic-Zugic; S M Friedman; K B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Insufficient expression of Fas antigen on helper T cells in Behçet's disease.

Authors:  S Nakamura; M Sugita; H Matoba; S Tanaka; F Isoda; S Ohno
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.